SMYRNA, Ga., July 2 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, is mentioned in two recent articles covering a historic HIV vaccine trial currently being conducted by the AIDS Research Consortium of Atlanta (ARCA) using a vaccine supplied by GeoVax.
The first article, titled "ARCA Seeks Volunteers For Historic HIV Vaccine Trial," appeared in the June 11 print and online editions of The Georgia Voice, a publication focused on Georgia's LGBT community. In the article, Voice reporter Matt Shafer notes that ARCA is currently seeking volunteers to help test the safety of the GeoVax vaccine, which has shown the potential of reversing HIV viral loads in HIV-positive individuals. He goes on to describe how the vaccine works and details the stringent requirements for participation. The article quotes ARCA's observation that this is the first therapeutic trial ever conducted using a promising HIV vaccine candidate from GeoVax.
The second article, titled "Georgia: AIDS Research Consortium of Atlanta Seeks Volunteers for Historic HIV Vaccine Trial," was posted on June 28 on the website The Body: The Complete HIV/AIDS Resource. It is an excerpt of the Voice piece, once again reviewing ARCA's search for trial subjects and stringent participation requirements.
GeoVax CEO Dr. Robert McNally commented, "As I pointed out to The Georgia Voice, we are hopeful that this vaccine will reproduce its effects in humans the way it did in tests conducted on primates. We anticipate that media coverage such as these articles will make it easier to recruit appropriate test subjects, allowing us to initiate the trial in a timely fashion and accelerate our quest to bring a viable vaccine to market."
To read The Georgia Voice's article in its entirety, please visit:
http://thegavoice.com/index.php/news/georgia-news-menu/507-arca-seeks-volu nteers-for-historic-hiv-vaccine-trial
To read The Body's article in its entirety, please visit: http://www.thebody.com/content/art57219.html About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus - that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines have demonstrated the ability to raise anti-HIV immune responses as well as for their safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will involve 225 participants at sites in the United States and South America. Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit http://www.geovax.com/.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete
vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
Contact At The Investor Relations Group: Investor Relations James Carbonara or Public Relations Janet Vasquez / Robin O'Malley (212) 825-3210
GeoVax Labs, Inc.
CONTACT: At The Investor Relations Group: Investor Relations: James
Carbonara, or Public Relations: Janet Vasquez or Robin O'Malley,
+1-212-825-3210
Web Site: http://www.geovax.com/
